Low-dose chemotherapy with leucovorin plus 5-fluorouracil for colorectal cancer can maintain host immunity

Anticancer Research

Volumn 27, Issue 1 B, 2007, Pages 675-679

  Kobayashi, Rie ^a   Yoshimatsu, Kazuhiko ^a   Yokomizo, Hajime ^a   Katsube, Takao ^a   Ogawa, Kenji ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

CD4+CD25+ T cell; Colorectal cancer; Host immunity; Low dose chemotherapy; sIL 2R

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; BEVACIZUMAB; CAPECITABINE; CD8 ANTIGEN; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; IRINOTECAN; OXALIPLATIN; SOLUBLE INTERLEUKIN 2 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MALE; METASTASIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; TH2 CELL; TREATMENT OUTCOME; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

AGED; ANTIGENS, CD4; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUCOVORIN; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; OXONIC ACID; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES; TEGAFUR; TIME FACTORS; TREATMENT OUTCOME;

EID: 33847728254     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New Engl J Med 343: 905-914, 2000.
2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047, 2000.
3. Delaunoit T, Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Findlay BP, Thomas SP, Salim M, Schaefer PL, Stella PJ, Green E and Mailliard JA: Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer 101: 2170-2176, 2004.
4. Goldberg RM: Advances in the treatment of metastatic colorectal cancer. Oncologist 10: 40-48, 2005.
5. NCCN Practice Guidelines on Oncology-v.2.2006. Colon Cancer Chemotherapy for advanced or metastatic disease. http://www.nccn.org/professionals/ physician_gls/PDF/colon.pdf
6. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF and Kabbinavar F: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23: 3502-3508, 2005.
7. Mokyr MB and Dray S: Interplay between the toxic effects of anticancer drugs and host antitumor immunity in cancer therapy. Cancer Invest 5: 31-38, 1987.
8. Mitchell MS and DeConti RC: Immunosuppression by 5-fluorouracil. Cancer 26: 884-889, 1970.
9. Ulrichs K, Yu MY, Duncker D and Muller-Ruchholtz W: Immunosuppression by cytostatic drugs? Behring Inst Mitt 74: 239-249, 1984.
10. Nio Y, Imai S, Shiraishi T, Ohgaki K and Tobe T: Lymphocvtes anticancer chemosensitivity testing in vitro - an approach to predict immunosuppressive effect of anticancer agents. J Clin Lab Immunol 29: 141-145, 1989.
11. Lee M, Yea SS and Jeon YJ: Paclitaxel causes mouse splenic lymphocytes to a state hyporeposive to lipoplysaccharide stimulation. Int J Immunopaharcol 22: 615-621, 2000.
12. Takahashi Y and Nishioka K: Survival without tumor shrinkage: re-evaluation of survival gain by cytostatic effect of chemotherapy. J Natl Cancer Inst 87: 1262-1263, 1995.
13. Ishibashi K, Yoshimatsu K, Yokomizo H, Umehara A, Yoshida K, Fujimoto T, Watanabe K, Katsube T, Naritaka Y and Ogawa K: Low-dose leucovorin and 5-Fluorouracil for unresectable multiple liver metastasis from colorectal cancer. Anticancer Res 25: 4747-4752, 2005.
14. Yoshimatsu K, Kato H, Ishibashi K, Hashimoto M, Umehara A, Yokomizo H, Yoshida K, Fujimoto T, Iwasaki K and Ogawa K: Second-line chemotherapy with low-dose CPT-11 and cisplatin for colorectal cancer resistant to 5-FU-based chemotherapy. Cancer Chemother pharmacol 52: 465-468, 2003.
15. Goto A, Yamada Y, Yasui H, Kato K, Hamaguchi T, Muro K, Shimada Y and Shirao K: Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol 7: 968-973, 2006.
16. World Health Organization: WHO handbook for reporting results of cancer treat-ment. WHO Offset publication no. 48, Geneva, 1979.
17. Brandes LJ and Israel LG: Treatment of advanced plasma cell myeloma with weekly cyclophosphamide and alternate-day prednisone. Cancer Treat Rep 66: 1413-1415, 1982.
18. Hande KR, Oldham RK, Fer MF, Richardson RL and Greco FA: Randomized study of high-dose versus low-dose methotrexate in treatment of extensive small cell lung cancer. Am J Med 73: 413-419, 1982.
19. Tilly H, Castaigne S, Bordessoule D, Sigaux F, Daniel MT, Monconduit M and Degos L: Low-dose cytosine arabinoside treatement for acute nonlymphocytic leukemia in elderly patients. Cancer 55: 1633-1636, 1977.
20. Mathé G, Halle-Pannenko O and Bourut C: Effectiveness of murine leukemia chemotherapy according to the immune state. Cancer Immunol Immunother 2: 139-141, 1977.
21. Lubet RA and Carlson DE: Therapy of the murine plasmacytoma MOPC 104E: Role of the immune response. J Natl Cancer Inst 61: 897-903, 1978.
22. Mokyr MB and Dray S: Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide. Cancer Res 43: 3112-3119, 1983.
23. Hilgard P, Pohl J, Stekar J and Voegeli R: Oxazaphosphorines as biological response modifiers: Experimental and clinical perspectives. Cancer Treat Rep 12: 155-162, 1986.
24. Holter W, Golman CK, Cassabo L and Nelson DL: Expression of functional IL-2 receptor by lipopolysaccharide and interferon-γ stimulated human monocytes. J Immunol 138: 2917-2930, 1987.
25. Rubin RA, Kurrman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R and Nelson DL: Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol 135: 3172-3178, 1985.
26. Nelson DL, Rubin LA, Kurrman CC, Fritz ME and Boutin B: An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro. J Clin Immunol 6: 114-118, 1986.
27. Pui CH, Ip SH, Rung P, Dodge RK, Berard CW, Crist WM and Murphy SB: High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma. Blood 70: 624-628, 1987.
28. Barak V, Ginzburg M, Kalickman I and Polliack A: Serum soluble interleukin-2 receptor levels are associated with clinical disease status and histopathological grade in non-Hodgkin's lymphoma and chronic lymphatic leukemia. Leuk Lymphoma 7: 431-438, 1992.
29. Stasi R, Zinzani PL, Galieni P, Lauta VM, Damasio E, Dispensa E, Dammacco F, Papa G and Tura S: Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma. Br J Haematol 88: 770-777, 1988.
30. Steis RG, Marcon L, Clark J, Urba W, Longo DL, Nelson DL and Maluish AE: Serum soluble IL-2 receptor as a tumor marker in patients with hairly cell leukemia. Blood 71: 1304-1309, 1988.
31. Motoi T, Uchiyama T, Uchini H, Ueda R and Araki K: Serum soluble interleukin-2 receptor levels in patients with adult T-cell leukemia and human T-cell leukemia/lymphoma virus type-I seropositive healthy carriers. Jpn J Cancer Res 79: 593-599, 1988.
32. Ishida H, Kumagai S, Umehara H, Sano H, Tagaya Y, Yodoi J and Imura H: Impaired expression of high affinity interleukin-2 receptor on activated lymphocytes from patients with systemic lupus erythematosus. J Immunol 139: 1070-1074, 1987.
33. Rubin LA and Nelson DL: The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med 11: 619-627, 1990.
34. Naumanik W and Chyczewska E: The clinical significance of serum soluble interleukin-2 recepter (sIL-2R) concentration in lung cancer. Folia Histochem Cytobiol 39: 185-186, 2001.
35. Naumanik W, Chyczewska E, Kovalchuk O, Talalaj J, Izycki T and Panek B: Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer. Ann Acad Med Bialist 49: 246-251, 2004.
36. Shibata M, Nezu T, Kanou H, Nagata Y, Kimura T, Takekawa M, Ando K and Fu-kuzawa M: Immunomodulatory effects of low dose cis-diaminedichloroplatinum (cisplatin) combined with UFT and PSK in patients with advanced colorectal cancer. Cancer Invest 20: 166-173, 2002.
37. Vuoristo MS, Laine S, Huhtala H, Parvinen LM, Hahka-Kemppinen M, Korpela M, Kumpulainen E and Kellokumpu-Lehtinen P: Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma. Eur J Cancer 37: 1629-1634, 2001.
38. Soker M, Colpan L, Ece A, Devecioglu C and Haspolat K: Serum levels of IL-1 beta, sIL-2R, IL-6, IL-8, and TNF-alpha in febrile children with cancer and neutropenia. Med Oncol 18: 51-57, 2001.
39. Shibata M and Takekawa M: Increased serum concentration of circulating soluble receptor for interleukin-2 and its effect as a prognostic indicator in cachectic patients with gastric and colorectal cancer. Oncology 56: 54-58, 1999.
40. Rovelli F, Lissoni P, Crispino S, Barni S, Fumagalli G, Paolorossi F and Tancini G: Increased levels of soluble interleukin-2 receptor in advanced solid tumors: a preliminary study. Tumori 74: 633-637, 1988.
41. Skog ALH, Wersall P, Ragnhammar P, Frodin JE and Mellstedt H: Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin ans sIL-2R, an indicator of immune suppression. Cancer Immunol Immunother 51: 255-262, 2002.
42. Sakaguchi S, Sakaguchi N, Asano M, Itoh M and Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155: 1151-1164, 1995.
43. Asano M, Toda M, Sakaguchi N and Sakaguchi S: Autoimmune disease as a consequence of developmental abnormality of T cell subpopulation. J Exp Med 184: 387-396, 1996.
44. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22: 531-562, 2004.
45. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6: 345-352, 2005.
46. Mills KH and McGuirk P: Antigen-specific regulatory T cells - their induction and role in infection. Semin Immunol 16: 107-117, 2004.
47. Vigouroux S, Yvon E, Biagi E and Brenner MK: Antigen-induced regulatory T cells. Blood 104: 26-33, 2004.
48. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR and June CH: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61: 4766-4772, 2001.
49. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS and Linehan DC: Prevalence of regu-latory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756-2761, 2002.
50. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98: 1089-1099, 2003.
51. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H and Fujii H: Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9: 4404-4408, 2003.
52. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L and Zou W: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949, 2004.
53. Yamashita T, Ueda Y, Fuji N, Itoh T, Kurioka H, Shirasaka T and Yamagishi H: Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil. Cancer Chemother Pharmacol 58: 183-188, 2006.
54. Melichar B, Touslova M and Vesely P: Effect of Irinotecan on the phenotype of peripheral blood leukocyte populations in patients with metastatic colorectal cancer. Hepatogastroentrol 49: 967-970, 2002.